Facebook
Twitter
LinkedIn
Forward
Diagnosing and Treating Early Neurotrophic Keratitis (CE Webcast)
Activity Description
Neurotrophic keratitis (NK) is a rare disease with serious consequences to a patient’s vision. It can be less challenging to recognize the tell-tale clinical signs of advanced stages of NK, making early cases of NK easier to overlook in today’s busy practices. Signs and symptoms of early stages of NK can overlap with those of more commonly seen ocular surface diseases, such as dry eye disease. In this webcast, Marjan Farid, MD, and Justin A. Schweitzer, OD, FAAO, present cases involving patients with early NK and discuss real-world application of diagnostic and treatment strategies that can provide the best opportunities to prevent progression in patients. The desired results of this activity are to aid clinicians in the early diagnosis and treatment of NK to prevent progression and improve patient outcomes.
Click HERE for a downloadable technician in-service tool on neurotrophic keratitis.
Target Audience
This educational activity is intended for ophthalmologists and optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Review clinical data on the treatment of patients with stage 1 NK
- Select evidence-based treatment options for patients with stage 1 NK
- Integrate evaluation of corneal sensitivity into assessment of ocular surface disease
Faculty
 | Marjan Farid, MD
|
 | Justin A. Schweitzer, OD, FAAO
|
Disclosure Policy
The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company. All relevant relationships with ineligible companies have been mitigated.
Faculty
Marjan Farid, MD, is a consultant for AcuFocus, Inc, Alcon, Aldeyra Therapeutics, Allergan, Bausch & Lomb Incorporated, Bio-Tissue, CorneaGen, Dompé US, Inc, Glaukos Corporation, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, and Zeiss; and is an advisory board member of AcuFocus, Inc, Alcon, Aldeyra Therapeutics, Allergan, Bausch & Lomb, Incorporated Bio-Tissue, CorneaGen, Dompé US, Inc, Glaukos Corporation, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, and Zeiss.
Justin A. Schweitzer, OD, is a consultant for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Avellino, Bausch & Lomb Incorporated, Dompé US, Inc, EyePoint Pharmaceuticals, Glaukos Corporation, Iveric Bio, Inc, Kala Pharmaceuticals, LKC Technologies, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Quidel Corporation, Reichert, Inc, RVL Pharmaceuticals, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, Visus Therapeutics, and Zeiss; is an advisory board member of Aerie Pharmaceuticals, Inc, Alcon, Allergan, Avellino, Bausch & Lomb Incorporated, Dompé US, Inc, Iveric Bio, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, RVL Pharmaceuticals, Inc, ScienceBased Health, Sight Sciences, Visus Therapeutics, and Zeiss; and is on the speakers bureau for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Glaukos Corporation, LKC Technologies, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, and Zeiss.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
COPE approved for 1.0 CE credit for optometrists.
COPE Course ID: 86019-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease
Administrator: 
This activity, COPE Activity Number 126617, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus LLC has received commercial support from Dompé US, Inc, for this activity in the form of an unrestricted educational grant.
The content of this COPE-Accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry, MedEdicus LLC, or Dompé US, Inc.
©2023 MedEdicus LLC. 294.2
Available Credit
- 1.00 COPE